Grifois, S.A.
GRFSDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| $0.16 | 2016-06-02 | 2016-06-06 | |
| July 9, 2026 | $0.11 | 2026-07-02 | 2026-07-02 |
| August 20, 2025 | $0.18 | 2025-08-12 | 2025-08-12 |
| June 14, 2021 | $0.46 | 2021-06-03 | 2021-06-04 |
| November 9, 2020 | $0.20 | 2020-10-30 | 2020-11-02 |
Dividends Summary
- Total Returned Value: Investors who held GRFS shares during this period received a total of $4.14 per share in dividend income.
- Latest Payout: The most recent dividend of $0.16/share was paid 9 days ago, on July 9, 2026.
- Dividend Growth: Since 2013, the dividend payout has grown by 1153.3%, from $0.01 to $0.16.
Company News
The hepatic encephalopathy market is projected to grow at 1.2% CAGR through 2036, valued at USD 900 million in 2025. Growth is driven by rising prevalence of chronic liver diseases, improved early diagnosis awareness, and emerging therapies from companies like Vedanta Biosciences, Yaqrit Discovery Ltd, and others. The US dominates with 60% market...
Canadian health care advocates are calling for the closure of Grifols plasma collection facilities and a public takeover following two deaths in Winnipeg linked to plasma sales, a third lawsuit for kidney damage, and Health Canada reports of non-compliance at four additional Grifols sites.
Pegasys market is poised for significant growth driven by rising hepatitis B prevalence, increasing healthcare spending, and expansion into oncology and hematology indications. However, the market faces headwinds from the rise of direct-acting antivirals and tariff-related cost pressures. North America leads in market share while Asia-Pacific is ...
The global Plasbumin-5 market is experiencing significant growth driven by rising surgical procedures, burn injuries, and expanding critical care infrastructure. North America leads the market while Asia-Pacific is the fastest-growing region. Grifols Therapeutics, the key market player, has strengthened its position through strategic partnerships...
The global blood plasma derivatives market is expected to double from $52.16 billion in 2025 to $104.30 billion by 2033, growing at a 9.08% CAGR. Growth is driven by increasing immune deficiencies, hematological disorders, and neurological conditions, with immunoglobulins representing 41.28% of the market. North America leads with 39.57% market s...
